Quercetin Targets Eye Aging at the Cellular Level — What the Evidence Shows

Age-related vision loss is driven by overlapping pathological processes — oxidative damage, chronic low-grade inflammation, pathological angiogenesis, and cellular senescence — that converge in diseases like age-related macular degeneration (AMD), cataract, diabetic retinopathy, and glaucoma. Existing treatments address individual mechanisms but rarely the full spectrum of aging-related dysfunction. Quercetin, a dietary flavonol abundant in capers, red onions, apples, berries, and green tea, has emerged as a multi-target candidate because its chemical structure (five hydroxyl groups enabling radical scavenging and metal chelation, plus a planar ring system enabling enzyme binding) allows it to engage several disease pathways simultaneously.

The review's central contribution is its framing of quercetin as a senotherapeutic agent. Senescent cells accumulate in aging ocular tissues — retinal pigment epithelium, trabecular meshwork, lens epithelium, and retinal ganglion cells — and drive disease through their senescence-associated secretory phenotype (SASP), releasing pro-inflammatory cytokines, proteases, and growth factors. Quercetin acts as both a senolytic (selectively inducing apoptosis in senescent cells by inhibiting anti-apoptotic BCL-2/BCL-XL pathways) and a senomorphic (suppressing SASP without killing cells). This dual action is proposed as a mechanism to slow or partially reverse ocular aging beyond what antioxidants alone can achieve.

For each disease, the review details specific mechanistic evidence. In AMD, quercetin suppresses VEGF-driven choroidal neovascularization, reduces RPE oxidative damage, and inhibits complement activation. In cataract, it protects lens epithelial cells from H₂O₂-induced apoptosis and protein aggregation by upregulating Nrf2/HO-1 antioxidant pathways. In diabetic retinopathy, it attenuates hyperglycemia-induced pericyte loss, blood-retinal barrier breakdown, and NLRP3 inflammasome activation. In glaucoma, it reduces intraocular pressure-related trabecular meshwork dysfunction, protects retinal ganglion cells from oxidative apoptosis, and modulates neuroinflammatory signaling.

Bioavailability is identified as the primary translational obstacle. Oral quercetin aglycone has absorption rates of roughly 24%, a plasma half-life of minutes to low hours, and undergoes rapid phase II conjugation and gut microbial metabolism. Glycoside forms (isoquercitrin, rutin) differ substantially in absorption efficiency. Advanced delivery systems — polymeric nanoparticles, solid lipid nanoparticles, nanoemulsions, cyclodextrin complexes, and polymeric micelles — are reviewed as strategies to improve ocular bioavailability, with some formulations showing several-fold improvements in preclinical models. Topical and intravitreal routes are discussed as ways to bypass systemic metabolism entirely.

The authors also highlight combination strategies: pairing quercetin with anti-VEGF agents (ranibizumab, bevacizumab) for AMD, with neuroprotective compounds for glaucoma, and with existing antidiabetic regimens for diabetic retinopathy. Clinical trials of quercetin in systemic conditions at 150–1000 mg/day have demonstrated acceptable safety, but dedicated ophthalmic trials are largely absent. The review concludes that while preclinical evidence is compelling, randomized controlled trials with standardized ocular formulations are urgently needed to translate quercetin's multi-mechanistic potential into clinical practice.